Speaking to the company’s first investor briefing focused on the gastrointestinal area, held recently in New York, Takeda Pharmaceutical Co. Ltd. president, COO and soon-to-be CEO Christophe Weber was clear: "GI is so important for us…and is seen as one of our key growth drivers along with oncology and the emerging markets."
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?